

Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication

- On June 12, 2024, <u>AstraZeneca announced</u> the FDA approval of <u>Farxiga (dapagliflozin)</u> and <u>Xigduo XR (dapagliflozin/metformin)</u>, as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
 - Farxiga and Xigduo XR were previously approved for this indication in adults only.
- Farxiga is also approved to reduce the risk of:
 - Sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
 - Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
 - Hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
- The approval of Farxiga and Xigduo XR for the expanded indication was based on a placebocontrolled, double-blind, randomized study in 157 patients aged 10 to 17 years with inadequately controlled type 2 diabetes mellitus. Patients were randomized to Farxiga or placebo as add-on to metformin, insulin or a combination of metformin and insulin.
 - At week 26, the change from baseline in HbA1c was -0.6 with Farxiga vs. +0.4 with placebo (difference -1.0, 95% CI: -1.6, -0.5; p < 0.001).
- Xigduo XR carries a boxed warning for lactic acidosis.
- In adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, the recommended starting dosage of Farxiga is 5 mg orally once daily to improve glycemic control. For additional glycemic control, the dosage can be increased to 10 mg orally once daily.
 - The starting dosage for Xigduo XR should be individualized based upon the patient's current regimen.
 - Refer to the Farxiga and Xigduo XR drug labels for complete dosing and administration recommendations, including for Farxiga's other approved indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.